Form 8-K - Current report:
SEC Accession No. 0001193125-23-020343
Filing Date
2023-01-31
Accepted
2023-01-31 16:09:07
Documents
14
Period of Report
2023-01-31
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d427060d8k.htm   iXBRL 8-K 25559
2 EX-99.1 d427060dex991.htm EX-99.1 18094
6 GRAPHIC g427060g0131081910378.jpg GRAPHIC 5595
  Complete submission text file 0001193125-23-020343.txt   182217

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tsha-20230131.xsd EX-101.SCH 2843
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tsha-20230131_lab.xml EX-101.LAB 18736
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tsha-20230131_pre.xml EX-101.PRE 11702
8 EXTRACTED XBRL INSTANCE DOCUMENT d427060d8k_htm.xml XML 3468
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

EIN.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39536 | Film No.: 23572642
SIC: 2836 Biological Products, (No Diagnostic Substances)